Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[KRAS status versus EGFR status in lung cancer therapy].

Bulletin du cancer - 1 Dec 2009

Lacroix L, Besse B, Bidart J-M, Bosq J

Abstract excerpt

Interest for development of molecular biomarkers tends to increase in clinical management of lung cancer. Indeed implementation in clinics of new molecules targeting epithelial growth factor (EGFR) such as erlotinib or gefitinib, rise several questions regarding the potential value of EGFR and KR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ErbB Receptors
Share to Erlotinib Hydrochloride
Share to Genes, ras

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Markers

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to ras Proteins

Source

Identifiers

PMID: 20034873
DOI: 10.1684/bdc.2009.0999

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20034873-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[KRAS status versus EGFR status in lung cancer therapy].PMID 20034873Read ↗

[Impact of KRAS in standard treatment of non-small cell lung cancer (NSCLC) patients in 2009: prognostic and predictive value].Semantic proximity Read ↗

Clinical testing for molecular targets for personalized treatment in lung cancer.Semantic proximity Read ↗

KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives.Semantic proximity Read ↗

KRAS mutation: should we test for it, and does it matter?Semantic proximity Read ↗

[Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma].Semantic proximity Read ↗

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.Semantic proximity Read ↗

[Molecular diagnostics of lung cancer].Semantic proximity Read ↗

[Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments].Semantic proximity Read ↗

Novel insights into the molecular origins and treatment of lung cancer.Semantic proximity Read ↗

Biomarkers and molecular profiling in non-small cell lung cancer: an expanding role and its managed care implications.Semantic proximity Read ↗

[Molecular pathology of lung cancer in routine diagnostic practice: 2017 update].Semantic proximity Read ↗

Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.